Dyne Therapeutics, Inc. (DYN) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 445.82M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 50.37M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -536.96M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $445.82M | (m) | $50.37M | $-536.96M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $392.77M | (m) | $45.91M | $-471.09M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $398.33M | (m) | $45.85M | $-468.18M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $384.71M | (m) | $45.10M | $-449.16M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $380.29M | (m) | $42.77M | $-440.93M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $343.31M | (m) | $38.98M | $-397.10M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $281.41M | (m) | $45.86M | $-343.89M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $258.44M | (m) | $41.12M | $-314.47M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $220.90M | (m) | $37.25M | $-271.08M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $217.76M | (m) | $35.26M | $-265.86M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $210.76M | (m) | $19.97M | $-242.16M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $185.11M | (m) | $18.07M | $-214.62M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $164.53M | (m) | $17.02M | $-194.63M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $152.06M | (m) | $15.31M | $-180.64M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $142.76M | (m) | $15.18M | $-170.96M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $151.87M | (m) | $17.36M | $-182.78M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $153.71M | (m) | $17.17M | $-183.26M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $130.92M | (m) | $18.38M | $-160.67M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $121.31M | (m) | $17.54M | $-150.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $101.11M | (m) | $15.74M | $-126.67M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $74.27M | (m) | $14.34M | $-97.42M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $57.74M | (m) | $10.18M | $-75.93M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $45.20M | (m) | $6.59M | $-58.65M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $11.04M | (m) | $26.00K | $-13.83M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |